A team uncovered an RNA‑guided mechanism by which STAT3 signaling shapes CD4+ T helper cell fate in non‑small‑cell lung cancer (NSCLC), detailing coordinated epigenetic and epitranscriptomic remodeling. The study, which maps STAT3’s downstream effects on T‑cell differentiation, links pathway modulation to tumor immune states and suggests targets for therapeutic manipulation of the tumor microenvironment. The work provides mechanistic rationale for strategies that combine STAT3 targeting with immunotherapy in NSCLC.